Title: Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
Journal: Chemical research in toxicology20150518
Title: Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.
Journal: Journal of molecular modeling20140401
Title: Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Journal: Mini reviews in medicinal chemistry20121101
Title: Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Journal: Journal of clinical pharmacology20121001
Title: Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Journal: Diabetes, obesity & metabolism20121001
Title: Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Journal: American journal of physiology. Renal physiology20121001
Title: Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Journal: Endocrine20120601
Title: Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
Journal: The Journal of clinical endocrinology and metabolism20120501
Title: An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Journal: Current diabetes reviews20120501
Title: DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Journal: Diabetes & metabolism20120401
Title: Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Journal: Diabetologia20120401
Title: Alogliptin benzoate for the treatment of type 2 diabetes.
Journal: Expert opinion on pharmacotherapy20120301
Title: Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Journal: Diabetes, obesity & metabolism20111201
Title: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Journal: Circulation20111122
Title: Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Journal: Diabetes, obesity & metabolism20111101
Title: Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Journal: Current medical research and opinion20111101
Title: EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
Journal: American heart journal20111001
Title: Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Journal: Current medical research and opinion20110901
Title: DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Journal: Journal of cardiovascular pharmacology20110801
Title: Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Journal: Expert opinion on investigational drugs20110601
Title: An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Journal: Contemporary clinical trials20110501
Title: [Alogliptin].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110501
Title: [A compounding agent of alogliptin and pioglitazone].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110501
Title: Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
Journal: Diabetes, obesity & metabolism20110401
Title: Alogliptin for the treatment of type 2 diabetes.
Journal: Drugs of today (Barcelona, Spain : 1998)20110201
Title: Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Journal: Hospital practice (1995)20110201
Title: Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Journal: Biochemical and biophysical research communications20110107
Title: The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Journal: European journal of medicinal chemistry20110101
Title: [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica20110101
Title: Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.
Journal: Vascular pharmacology20110101
Title: Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Journal: Experimental diabetes research20110101
Title: Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Journal: PloS one20110101
Title: DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.
Journal: Atherosclerosis20101201
Title: DPP-4 inhibitors: what may be the clinical differentiators?
Journal: Diabetes research and clinical practice20101101
Title: Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Journal: Diabetes care20101101
Title: Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.
Journal: Current diabetes reviews20101101
Title: Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Journal: Drugs20101022
Title: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Journal: Clinical pharmacokinetics20100901
Title: Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Journal: The American journal of the medical sciences20100801
Title: Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Journal: Diabetes, obesity & metabolism20100301
Title: The physiologic role of incretin hormones: clinical applications.
Journal: The Journal of the American Osteopathic Association20100301
Title: Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Journal: International journal of clinical pharmacology and therapeutics20100101
Title: Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Journal: Vascular health and risk management20100101
Title: Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
Journal: Diabetes, obesity & metabolism20091201
Title: Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Journal: Journal of the American Geriatrics Society20091101
Title: Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Journal: Journal of clinical pharmacology20091001
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Journal: Current medical research and opinion20091001
Title: A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Journal: Life sciences20090717
Title: Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Journal: British journal of pharmacology20090601
Title: Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Journal: The Journal of pharmacology and experimental therapeutics20090501
Title: Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry20090301
Title: DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Journal: Advances in therapy20090301
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Journal: Diabetes, obesity & metabolism20090201
Title: Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Journal: Expert opinion on pharmacotherapy20090201
Title: The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Journal: European journal of pharmacology20090114
Title: Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Journal: International journal of clinical practice20090101
Title: New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
Journal: The Diabetes educator20090101
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Journal: Diabetes care20081201
Title: Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Journal: European journal of pharmacology20080728
Title: Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Journal: European journal of pharmacology20080707
Title: Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Journal: Current opinion in investigational drugs (London, England : 2000)20080401
Title: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Journal: Clinical therapeutics20080301
Title: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Journal: Clinical therapeutics20080301
Title: Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Journal: Current topics in medicinal chemistry20080101
Title: Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Journal: Journal of medicinal chemistry20070517
Title: Feng J, et, al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300.
Title: Ta NN, et, al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35.
Title: Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187.
Title: Asakawa T, et, al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6.
Title: Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54.
